A Phase 2 interventional study of Cannabis oil and Placebo in Hidradenitis Suppurativa, sponsored by TO Pharmaceuticals. Withdrawn at 1 site in Israel. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-08-04.
Sponsored by TO Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Hidradenitis Suppurativa with a site in Israel — 1 open to participants now, 3 under way, 2 of them phase 3. Hidradenitis Suppurativa · Israel.
Among the 11 studies in Hidradenitis Suppurativa with a site in Israel, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2020, is one of 2 in phase 2, and was the 4th registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →1 of the 11 studies in Hidradenitis Suppurativa with a site in Israel is open now. Recruiting first, the newest first:
Sanofi · Sites in Israel, United States, Australia and 16 more countries
Ages 18+
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 8
First in 2016; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 527 across the 10 interventional studies, 236 across the 1 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 6 most frequent:
TO Pharmaceuticals is the lead sponsor of 3 studies on the registry; none are open to participants now.
TO Pharmaceuticals has 1 study filed under Hidradenitis Suppurativa — fewer than ten, so there is no comparison to draw.
2 of the studies in Hidradenitis Suppurativa with a site in Israel that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468228Phase 3AbbVieA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12 |
| NCT07170917SanofiBrivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa | 2027-02-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Hidradenitis Suppurativa with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hidradenitis Suppurativa (HS), is a chronic skin disease, manifested as inflamed areas of hair follicles around apocrine sweat glands found in areas most commonly the axillae, inguinal and anogenital regions. Patients experience great deal of physical pain as well as profound psychological problems. HS patients may also be prone to health complications and diseases. Treatment to date is limited and consist mainly of antibiotic administration and novel biological drug with up to 40% efficiency. Recently it was shown that cannabinoids reduces the folliculo pilosebaceous activity, most likely due to activating arachnoiditis, lipostat , anti-proliferative and anti-inflammatory agents and reduce inflammation inducing cytokines.
Forty participants will be recruited over two years. After determine eligibility by examining the study criteria for inclusion and exclusion, the patient will be asked to sign the informed consent form.
The YAKAR form of medical cannabis license application and a confidentiality waiver form will be sent to the YAKAR. The physician will explain to the patients that his/her participation in the trial can be terminated at any time and will explain the medical license conditions: It is absolutely forbidden to:
When the patient license arrives, the patient will be scheduled an appointment for the first visit of the trial at the hospital. Tikun-Olam will be informed and asked to supply the patient product on the visit day. The copy of the patient's license will be included into the trial source documents.
The participants will be randomly assigned in a 1:1 ratio to receive Avidekel oil or placebo oil. Patients will receive the oils as drops applied under the tongue 3 times a day.
The duration of study participation for each subject is expected to be 12 weeks (84 days), about 4 weeks from visit 0 until receiving the license and 8 weeks trial,of which, six weeks of dose titration. Over the course of twelve weeks, four visits will be conducted and there will be 3 telephone evaluations. During first visit screening and enrolment will be conducted. The second visit will take place four weeks later where patients will receive the oils and start the trial, followed by a phone call evaluation at day 5-7 after starting the treatment and at week 2±2 days. Than a visit approximately four weeks later, following another phone call evaluation at week 5±2 days from treatment beginning, F Last visit will be conducted at week 8±3 days. In each visit, the relevant variables will be collected (Please refer to Table 3. Schedule of events). At the end of the eight-week experiment, patients from the treatment and control groups will be given the option to use the Avidekel oil for a period of one year. First, all the patients will use the drug in the open label phase for 8 weeks, during this period 3 phone calls and 2 visits in the hospital will be conducted, using PI-NRS and HS-PGA score to evaluate treatment success. Patients who will have at least 1 point reduction on the HS-PGA score will be permitted to continue to the 1 year follow-up. During that period 2 visits, six months and one year, will be conducted and the relevant variables will be collected (see Table 3). All visits will take place at the hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The cannabis oil, sort T1/C20 CBD as categorized by the MOH guidelines will be made from Avidekel strain and olive oil extract. Avidekel oil contains Δ9-Tetra-Hydrocannabinol (Δ9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% Δ9-THC. Each Avidekel oil drop is approximately 0.04 ml in volume containing about 12 mg CBD and 0.6 mg Δ9-THC.
Drug: Cannabis oil
Patients in the control group will receive placebo oil containing olive oil and Chlorophyll.
Drug: Placebo
T1/C20 CBD
Also known as: Avidekel Oil
Olive oil with chlorophyl
Also known as: Olive oil with chlorophyl
Clinical response
1 point reduction in HS-PGA score in treatment vs. control at week 8
Time frame: From Week 0 to Week 8
Safety: Participants experiencing Adverse Events (AE's) or Serious Adverse Events (SAE's)
Participants experiencing Adverse Events (AE's) or Serious Adverse Events (SAE's)
Time frame: Week 3, Week 6, six months and 12 months
Efficacy: Hidradenitis suppurativa Severity Index (HSSI)
Hidradenitis suppurativa Severity Index (HSSI)
Time frame: 6 weeks, six months and 12 months
Clinical response
Hidradenitis Suppurativa Clinical Response (HiSCR)
Time frame: 6 weeks of treatment
Changes from baseline
Dermatology Quality of Life Index (DLQI)
Time frame: From Week 0 to Week 6, six months and 12 months
Efficacy on pain levels: VAS pain scale
VAS pain scale 11-point numerical pain rating scale
Time frame: From Week 0 to Week 8, 16 weeks, six months and 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Sep 2020; primary completion for Sep 2022, 24 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabis sativa flowering TOP